期刊文献+

高龄男性2型心肾综合征患者血清睾酮水平的研究 被引量:3

Serum testosterone level in elderly male patients with type 2 cardiorenal syndrome
下载PDF
导出
摘要 目的:观察高龄男性2型心肾综合征患者血清睾酮水平的变化。方法:入选年龄≥75岁的慢性心力衰竭男性患者150例,将其中2型心肾综合征者设为观察组(n=69),其余设为对照组(n=81)。检测并比较两组患者血清睾酮、胱抑素-C、N末端B型利钠肽原(NT-proBNP)、超敏C反应蛋白等指标。结果:观察组血清胱抑素-C、NTproBNP、超敏C反应蛋白水平均高于对照组(P<0.05)而血清睾酮水平显著低于对照组,为(12.7±6.08)nmol/L对(22.07±7.53)nmol/L,P<0.01;其余指标组间均无统计学差异。结论:高龄男性慢性心力衰竭患者中,发生2型心肾综合征者血清睾酮水平降低。 Objective:To observe the change of serum testosterone levels in elderly male patients with type 2 cardiorenal syndrom (CRS). Methods:A total of 150 male patients with chronic heart disease over the age of 75 selected into this study were assigned to observation group (type 2 CRS,69 cases)and control group (non-type 2 CRS,81 cases).Serum testosterone,cystatin-C,N-terminal pro-brain natriuretic peptide (NT-proBNP),high sensitivity C-reactive protein (hs-CRP)and some other serological indexes were determined. Resuits:The serum levels of cystatin-C,NT-proBNP and hs-CRP were all higher (P 〈0.05),but serum testosterone was significantly lower[(12.7 ±6.08)nmol/L vs. (22.07±7.53)nmol/L,P 〈0.01 ]in observation group than those in control group. Conciusion:The serum testosterone level may decrease in elderly male patients with type 2 CRS.
出处 《国际心血管病杂志》 2014年第5期350-352,共3页 International Journal of Cardiovascular Disease
关键词 血清睾酮 高龄 男性 2型心肾综合征 Testosterone Elderly Male Type 2 cardiorenal syndrome
  • 相关文献

参考文献14

  • 1deCastroFD,ChavesPC,LeiteMoreiraAF.Cardiorenalsyndromeanditspathophysiologicalimplications[J].RevPortCardiol,2010,29(10):1535-1554.
  • 2CarlssonAC,LarssonA,HelmerssonKarlqvist,etal.Urinarykidneyinjury molecule1 andincidenceofheartfailureinelderlymen[J].JEurJHeartFail,2013,15(4):441-446.
  • 3FrancomanoD,BruzzichesR,NataliM,etal.Cardiovasculareffectoftestosteronereplacementtherapyinagingmale[J].ActaBiomed,2010,81 (Suppl1):101-106.
  • 4吴志俊,张凤如,金玮,刘艳.重组人脑钠肽治疗冠心病合并急性心力衰竭疗效的性别差异[J].国际心血管病杂志,2013,40(6):394-396. 被引量:11
  • 5GuderG,FranizS,BauersachsJ,etal.Low circulatingandrogensand mortality riskin heartfailure[J].Heart,2010,96(7):504-509.
  • 6FukaiS,AkishitaM,YamadaS,etal.Plasmasexhormonelevelsandmortalityindisabledoldermenand women [J].GeriatrGerontolInt,2011,11(2):196-203.
  • 7RoncoC,Haapio M,HouseAA,etal.Cardiorenalsyndrome[J].JAm CollCardiol,2008,52(19):1527-1539.
  • 8Campelo AE,CutiniPH,MassheimerVL.Testosteronemodulatesplateletaggregation and endothelialcellgrowththroughnitricoxidepathway [J].JEndocrinol,2012,213(1):77-87.
  • 9NguyenCT,AaronsonA,MorrisseyRP,etal.Mythsandtruthsofgrowthhormoneandtestosteronetherapyinheartfailure[J].Expert Rev Cardiovasc Ther,2011,9(6):711-720.
  • 10HanY,FuL,Sun W,etal.Neuroprotectiveeffectsoftestosteroneuponcardiacsympatheticfunctioninratswithinducedheartfailure[J].EurJPharmacol,2009,619(1-3):68-74.

二级参考文献9

  • 1O'Meara E, Clayton T, McEntegart MB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program[J]. Circulation, 2007, 115(24) : 3111-3120.
  • 2Shah RU, Klein L, Lloyd-Jones D1VL Heart failure in women:epidemiology, biology and treatment[J]. Women's health, 2009, 5(5): 517 527.
  • 3Hsich EM, Pina If: Heart failure in women: a need for prospeetive data [J] J Am Coll Cardiol, 2009, 54 (6) : 491 498.
  • 4Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group[J] N Engl J Med, 1987, 316 (23): 1429-1435.
  • 5Colucei WS, E:kayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group[J]. N Engl J Med,2000,343(4) :246-253.
  • 6Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [J]. Eur J Heart Fail,2008,10(10):933-989.
  • 7Yamac H, Bultmann I, Sliwa K, et al. Prolactin: a new therapeutic target in peripartum cardiomyopathy[J]. Heart, 2010,96(17) :1352-1357.
  • 8Christ M, Laule-Kilian K, Hochholzer W, et al. Gender- specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the 13 type natriuretic peptide for acute shortness of breath evaluation study [J] J Am Coll Cardiol, 2006, 48 (9): 1808-1812.
  • 9吴志俊,金玮,张凤如,刘艳.利钠肽家族基因与心血管疾病研究新进展[J].遗传,2012,34(2):127-133. 被引量:11

共引文献10

同被引文献7

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部